http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0039163-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67abdb148f7b1b6654bc11ed3ae3cc39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c72af84a338bc50a93fd0c8f64a01e94 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate | 1999-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb378d5c23ac2b6a04fdc8cf68513880 |
| publicationDate | 2000-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0039163-A1 |
| titleOfInvention | Modification of interferon alpha production |
| abstract | A process for the production of α-interferon comprising the steps: i) inducing of human leukocytes by means of a virus; ii) treating the leukocytes with an enhancing agent selected from: a) Xanthine, pyrimidinol and pyrimidinone or derivatives of anyone thereof, such as theophylline, 2-amino-5-bromo-6-methyl-4 pyriminidol or thymine; b) an organic solvent selected from the group consisting of non-aromatic ketones, aliphatic or cyclic amides, alkylated aliphatic or cyclic urea derivatives and aliphatic or cyclic sulfoxides, such as N-methyl-2-pyrrolidinone, acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, 4-methyl-2-pentanone-N-ethyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or N,N,-dimethylacetamide; or a combination of the compounds from a) with an organic solvent from b). |
| priorityDate | 1998-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 252.